FindTrial
Sign In

Interleukin gene and its association with survival in Stage IV Lung Cancer

A Study on Association of Interleukin Gene (IL) Expression and Progression Free Survival in Stage IV Non-Small Cell Lung Cancer in a Tertiary Care Hospital - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/10/058696
Enrollment
110
Registered
2023-10-16
Start date
Unknown
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung

Interventions

Intervention1: NIL: NIL

Sponsors

Institute of Medical sciences and SUM Hospital SOA University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients age = 18 yrs. 2. Histopathology/cytology-proven NSCLC 3. Stage IV disease measured by CECT/PET CT 4. Adequate organ function.

Exclusion criteria

Exclusion criteria: 1. Consent refusal 2. Patients already on chemotherapy

Design outcomes

Primary

MeasureTime frame
Association of Interleukin Gene (IL) Expression and Progression-Free Survival in Stage IV Non-Small Cell Lung Cancer Timepoint: Baseline, 12 weeks, 24 weeks, 36 weeks—

Secondary

MeasureTime frame
Association of inflammatory genes with PD-L1 (Programmed Death Ligand ) & Desmocollin 3 Gene Expression in Stage IV Non-Small Cell Lung Cancer Timepoint: Baseline—

Countries

India

Contacts

Public ContactDr Santhosh Meedimale

Institute of Medical sciences and SUM Hospital

soumyasurathpanda@soa.ac.in8895370579

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026